A New Host Strain-Plasmid Combination
A New Core of CLD and Microbial Optimization
At KBI Biopharma, our PUREcoli cell line is our proprietary, high-producing E. coli cell line. As part of the KBI PUREplatform™, PUREcoli can be expertly paired with PUREplasmids™ and PUREmedia™ and our cutting-edge fermentation process that fits together into a complete service package, catered to your needs.
E. coli has long been implemented as a therapeutic protein factory due to its simplicity, tractability, and wealth of information characterizing the bacteria. Recent advancements in genetic engineering, analytics, and strain screening now allow for the reimagining of E. coli as an optimal protein factory - not just a common one or as an expression system artifact.
While common E. coli protein expression strains alter as many as five genes to improve one aspect of recombinant E. coli protein expression, KBI has created a platform E. coli with ~1,000 genes altered and roughly 1 Mbp of DNA removed. Every idea aimed at optimizing the safety, identity, strength, purity, and quality (SISPQ) of recombinant proteins has been rolled into an optimal genotype associated with reduced translational and post-translational modifications, excess genes, virulent genes, ad destabilizing genes, all layered on top of an improved metabolism. The result is a PURE, efficient platform expression strain: PUREcoli.
Just one way KBI is Doing More with Microbes.
KBI PUREcoli grows nearly 50% faster in fully defined media and to around 2X the cell density (up to 40% WCW) as compared to common E. coli strains. The faster growth reduces fermentation times and the 2X higher cell density allows for 2X the potential titer. In addition, the KBI PUREcoli genotype is associated with higher stability and yields robust, stable E. coli protein expression. This, in combination with higher cell density, allows for exceptionally high potential titers, even for difficult-to-express proteins.
.png?width=175&height=175&name=MicrosoftTeams-image%20(75).png)
